Metalloproteinases and their inhibitors in tumor angiogenesis
- PMID: 15729716
- DOI: 10.1002/ijc.20945
Metalloproteinases and their inhibitors in tumor angiogenesis
Abstract
Angiogenesis is the process by which new blood vessels are formed from preexisting vasculature. It is an essential feature of the female reproductive cycle, embryonic development and wound repair. Angiogenesis has also been identified as a causal or contributing factor in several pathologies, including cancer, where it is a rate-limiting step during tumor progression. Matrix metalloproteinases (MMPs) are a family of soluble and membrane-anchored proteolytic enzymes that can degrade components of the extracellular matrix (ECM) as well as a growing number of modulators of cell function. Several of the MMPs, in particular the gelatinases and membrane-type 1 MMP (MT1-MMP), have been linked to angiogenesis. Potential roles for these proteases during the angiogenic process include degradation of the basement membrane and perivascular ECM components, unmasking of cryptic biologically relevant sites in ECM components, modulation of angiogenic factors and production of endogenous angiogenic inhibitors. This review brings together what is currently known about the functions of the MMPs and the closely related ADAM (a disintegrin and metalloproteinase domain) and ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) families in angiogenesis and considers how this information might be useful in manipulation of the angiogenic process, with a view to constraining tumor progression.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
Metalloproteinases and their inhibitors in angiogenesis.Expert Rev Mol Med. 2003 Sep 22;5(23):1-39. doi: 10.1017/S1462399403006628. Expert Rev Mol Med. 2003. PMID: 14585170 Review.
-
Matrix metalloproteinases and angiogenesis.J Cell Mol Med. 2005 Apr-Jun;9(2):267-85. doi: 10.1111/j.1582-4934.2005.tb00355.x. J Cell Mol Med. 2005. PMID: 15963249 Free PMC article. Review.
-
Matrix metalloproteinases (MMPs) in health and disease: an overview.Front Biosci. 2006 May 1;11:1696-701. doi: 10.2741/1915. Front Biosci. 2006. PMID: 16368548 Review.
-
[The role of matrix metalloproteinases and their tissue inhibitors in angiogenesis].Pol Merkur Lekarski. 2006 Jul;21(121):80-5. Pol Merkur Lekarski. 2006. PMID: 17007300 Review. Polish.
-
Pericellular proteases in angiogenesis and vasculogenesis.Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28. doi: 10.1161/01.ATV.0000209518.58252.17. Epub 2006 Feb 9. Arterioscler Thromb Vasc Biol. 2006. PMID: 16469948 Review.
Cited by
-
High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.Cancer Invest. 2012 Jun;30(5):343-63. doi: 10.3109/07357907.2012.664670. Cancer Invest. 2012. PMID: 22571338 Free PMC article.
-
Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.Cancer Res. 2007 Dec 15;67(24):11760-8. doi: 10.1158/0008-5472.CAN-07-3233. Cancer Res. 2007. PMID: 18089806 Free PMC article.
-
Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation.Integr Cancer Ther. 2022 Jan-Dec;21:15347354221096766. doi: 10.1177/15347354221096766. Integr Cancer Ther. 2022. PMID: 35796303 Free PMC article. Review.
-
Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice.J Clin Invest. 2008 May;118(5):1944-54. doi: 10.1172/JCI33680. J Clin Invest. 2008. PMID: 18398510 Free PMC article.
-
Molecular regulation of tumor angiogenesis and perfusion via redox signaling.Chem Rev. 2009 Jul;109(7):3099-124. doi: 10.1021/cr8005125. Chem Rev. 2009. PMID: 19374334 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
